KZIA
Kazia Therapeutics Limited
stock NASDAQ ADR

Watching KZIA and considering puts depending on what it does after open. I'm seeing too many red flags namely risk of delisting for too low a market cap, lack of working capital to possibly bring a drug to market, and too much possibility of an offering being dropped. I currently have no position. That is all. Thanks for your attention to this matter.

Kazia reports first-ever Immune Complete Response (iCR) in metastatic TNBC - in a patient who had ALREADY FAILED prior anti-PD-1 therapy!
Complete radiological remission >6 months on paxalisib + Keytruda.
CEO Dr. John Friend: “A pivotal moment for Kazia — validates our approach of combining PI3K inhibition with immune checkpoint blockade and underscores paxalisib’s potential to drive durable anti-tumor immunity.” Translation: Paxalisib can rescue immunotherapy resistance and create long-lasting immune attack !
Why this is insanely bullish: • Metastatic TNBC is one of the deadliest cancers • Median survival after PD-1 failure <12 months • Complete responses are basically don’t exist here
Their drug called paxalisib, is the most broad of all PI3k drugs. Reduced levels of dosing and in combo for the first time with Keytruda, is reason for how different results are being achieved. In my understanding: 🚨Paxalisib makes cancer cells visible for targeting by immunotherapy‼️
Kazia has a 1.52m float and a marketcap of 10.16 mil ! But also almost no free cash!
Rumors - in talks with $JAZZ for a buyout !
One of the riskiest biotech names I’ve ever traded !
Active in GBM, DIPG, breast cancer brain metastases, and other tough CNS settings. Pivotal GBM AGILE readout + multiple combination studies upcoming. The Ticker is $ KZIA

Watching KZIA and considering puts depending on what it does after open. I'm seeing too many red flags namely risk of delisting for too low a market cap, lack of working capital to possibly bring a drug to market, and too much possibility of an offering being dropped. I currently have no position. That is all. Thanks for your attention to this matter.

Kazia reports first-ever Immune Complete Response (iCR) in metastatic TNBC - in a patient who had ALREADY FAILED prior anti-PD-1 therapy!
Complete radiological remission >6 months on paxalisib + Keytruda.
CEO Dr. John Friend: “A pivotal moment for Kazia — validates our approach of combining PI3K inhibition with immune checkpoint blockade and underscores paxalisib’s potential to drive durable anti-tumor immunity.” Translation: Paxalisib can rescue immunotherapy resistance and create long-lasting immune attack !
Why this is insanely bullish: • Metastatic TNBC is one of the deadliest cancers • Median survival after PD-1 failure <12 months • Complete responses are basically don’t exist here
Their drug called paxalisib, is the most broad of all PI3k drugs. Reduced levels of dosing and in combo for the first time with Keytruda, is reason for how different results are being achieved. In my understanding: 🚨Paxalisib makes cancer cells visible for targeting by immunotherapy‼️
Kazia has a 1.52m float and a marketcap of 10.16 mil ! But also almost no free cash!
Rumors - in talks with $JAZZ for a buyout !
One of the riskiest biotech names I’ve ever traded !
Active in GBM, DIPG, breast cancer brain metastases, and other tough CNS settings. Pivotal GBM AGILE readout + multiple combination studies upcoming. The Ticker is $ KZIA